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Abstract 
A global DNA hypomethylation might activate oncogene transcription, thus promoting car -
cinogenesis and tumor development. S-Adenosylmethionine (SAM) serves as a major methyl 
donor in biological transmethylation events. T h e   o b j e c t   o f   t h i s   s t u d y   i s   t o explore the influence 
o f   S A M   o n   t h e   s t a t u s   o f   m e t h y l a t i o n   a t   t h e   p r o m o t e r   o f  the oncogenes c-m y c ,   H -ras  and 
tumor-suppressor gene p1 6   ( I N K 4 a ) ,   a s   w e l l   a s   i t s   i n h i b i t o r y   e f f e c t   o n  cancer cells. The results 
indicated that SAM treatment inhibited cell growth in gastric cancer cells and colon cancer 
cells, and the inhibition efficiency was significantly higher than that in the normal cells. Under 
standard growth conditions, C-m y c   a n d   H -ras promoters were hypomethylated in gastric 
c a n c e r   c e l l s   a n d   c o l o n   c a n c e r   c e l l s .   S A M   t r e a t m e n t   r e s u l t e d   i n   a   h e a v y   m e t h y l a t i o n   o f   t h e s e  
promoters, which consequently downregulated mRNA and protein levels. In contrast, there 
was no significant difference in mRNA and protein levels of p16 (INK4a) with and without 
SAM treatment. S A M   c a n   e f f e c t i v e l y   i n h i b i t   t h e   t u m o r   c e l l s   g r o w t h   b y   r e v e r s i n g   t h e   D N A  
h y p o m e t h y l a tion on promoters of oncogenes, thus down-regulating their expression. With no 
influence on the expression of the tumor suppressor genes, such as P16, SAM could be used as 
a potential drug for cancer therapy. 
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Introduction 
The epigenome, which  controls  the  differential 
expression of genes in specific cells, is composed of 
DNA  methylation  (covalent)  and  modifications  that 
occur  on  DNA-associated  components,  such  as  his-
tones (noncovalent). Tumorigenesis and metastasis is 
relevant to genetic and epigenetic changes. One of the 
hallmarks of cancer is a massive  aberration of DNA 
methylation. While global DNA is hypomethylated, 
some key regions such as tumor suppressor genes are 
hypermethylated.  Understanding  the  mechanisms 
underlying these epigenetic changes  would  provide 
important  information  for  cancer  diagnosis  and 
therapy. 
Epigenetics is  the study  of  changes  in gene ex-
pression and other phenotypes caused by DNA  me-
thylation  and  histone  modification,  rather  than 
changes in DNA sequence. DNA methylation plays a 
critical  role  in  regulating  and  reprogramming  gene 
expression  patterns  in  mammalian  cells  [1-3].  It  is 
known that changes in methylation patterns are  cor-Int. J. Biol. Sci. 2010, 6 
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related to the development and progression of tumors 
[4-6]. Accumulated evidence demonstrates that DNA 
hypermethylation in promoter regions silences  gene 
transcription,  which  is  proposed  as  an  important 
mechanism for inactivating tumor suppression genes 
during  tumorigenesis.  Recently,  efforts  have  been 
made  to  reverse  the  hypermethylation  status  of  tu-
mor-suppressor genes by  using DNA demethylation 
agents [7-9]. However, hypomethylation also plays an 
important  role  in  carcinogenesis  and  tumor  devel-
opment.   I t   h a s   b e e n   found  that  DNA  hypomethyla-
tion causes genomic instability and increases the fre-
quency  of  transposon  insertion  mutation  [10,  11]. 
Furthermore,  a global DNA  hypomethylation might 
activate oncogene transcription, thus promoting car-
cinogenesis  and  tumor  development.  Moreover, 
emerging  data  suggest  that  hypomethylation  is  also 
involved in cancer  metastasis and invasion  by  acti-
vating particular genes [12, 13].  
S-A d e n o s y l m e t h i o n i n e   ( S A M   o r   A d o   M e t )   p l a y s  
a   p i v o t a l   r o l e   a s   a   m e t h y l   d o n o r   i n   m e t h y a t i o n   r e a c-
tions.  SA M   i s   f o r m e d   f r o m   m e t h i o n i n e   a n d   A T P   b y  
methionine  adensyltransferase  (MAT).  It  has  been 
r e p o r t e d   t o   s e r v e   a s   a   t h e r a p e u t i c   r e a g e n t   f o r   c a n c e r  
treatments [14,  15]. In  this study,  we  explored how 
DNA  methylation  of  promoter  regions  affects  gene 
expression in cancer and normal cells. We found that 
in  human  gastric  cancer  cells (MGC-803) and  colon 
cancer cells (HT-29), the oncogenes C-myc and H-ras 
were hypomethylated and SAM treatment increased 
their  methylation  levels,  thus  suppressing  gene  ex-
pressions.   I n   c o n t r a s t ,   t h e   t u m o r   s u p p r e s s o r   g e n e   P 1 6  
was already hypermethylated so SAM treatment had 
n o   e f f e c t   o n   i t s   e x p r e s s i o n .   A d d i t i o n a l l y ,   w h i l e   S A M  
was  able  to  slow  down  tumor  cell  growth  by 
down-regulating c-myc and H-ras expression, normal 
cells were not affected by SAM and had unchanged 
expression of c-myc, H-ras and P16. Thus, we propose 
t h a t   S A M   c o u l d   b e   u s e d   f o r   c a n c e r   t h e r a p y   v i a   s p e-
cifically  suppressing  tumor,  but  not  normal,  cell 
growth. 
Materials and Methods 
Cell culture and treatment with SAM 
The human gastric cancer cell line (MGC-803), 
colon cancer cell line (HT-29)  and normal liver cell 
line (Chang liver cell line) were obtained from Insti-
tute  of  Tianjin  Huanhu Hospital,  China.  These  cells 
w e r e   c u l t u r e d   i n   R P M I   1 6 40 medium supplemented 
with 10% fetal  bovine  serum,  containing 100 IU/mL 
penicillin and  100 µg/mL streptomycin in a humidi-
fied incubator with 5% CO2 a n d   9 5 %   a i r   a t   37 ºC. After 
24h  of  culturing, an adequate number of cells  were 
randomly  selected  from  these  two  cell  lines  and 
treated  with  10μmol/L  SAM  (Promega,  USA).  Un-
t r e a t e d   c e l l s   ( n o   d r u g   i n   m e d i u m )   w e r e   u s e d   a s   a  
control.  
MTT Assay and colony formation assay 
Cells  in  logarithmic  growth  were  seeded  at  a 
density of 5×103 cells/well in 96-well plates in 200µl 
volume  media.  10   µ l   o f   M T T   s o l u t i o n   ( 5   m g / m L in 
P B S )   w a s   a d d e d   i n t o   e a c h   w e l l   a n d   c e l l s   w e r e   i n c u-
bated at 37 º C   f o r   4   h  allowing the MTT to be metabo-
lized.  The  supernatant  was  removed  and  100   µ l   o f  
DMSO was added into each well to dissolve formazan 
crystals. T h e   a bsorbance of the solutions with dye was 
measured at 492nm o n   a   m u l t i -well spectrophotome-
ter  (Bio-Tek).  The  inhibition  effect  of  the  different 
g r o u p s   o f   c e l l s was calculated with the following the 
formula: Inhibition effect (%) = (1- Absorbance value 
of S A M   t r e a t e d   g r o u p   /  Absorbance value of control 
group) × 100%. Trypsinized cells were seeded for co-
lony formation assay in 100-mm dishes. After 16 days 
c o l o n i e s   w e r e   f i x e d   a n d   s t a i n e d   w i t h   a   m i x t u r e   o f  
6.0% glutaraldehyde and 0.5% crystal violet. 
Methylation specific PCR assay (MSP) for DNA 
methylation in the promoter regions of c-myc, 
H-ras and p16 (INK4a) 
Isolated  genomic  DNA  was  bisulfate-treated 
with a DNA Modification kit (TaKaRa Co.) following 
the  protocol provided by the  manufacturer.  Treated 
D N A   w a s   p u r i f i e d   u s i n g   a   W i z a r d   D N A   c l e a n -up 
system (Promega), DNA was ethanol precipitated and 
diluted in 30 µl of double-distilled water. Methylation 
specific PCR (MSP) was carried out at 95 ºC for 5 mi-
nutes,  followed  by  95 ºC for 30 seconds, 58 ºC for 30 
seconds and 72 ºC for 40 seconds. After 30 cycles, an 
additional incubation at 72 ºC f o r   1 0  minutes w a s   u s e d  
to finish extension.  Primers  used  for amplifying the 
promoter  regions  of  c-myc,  H-ras  and  p16  (INK4a) 
(with or without methylation) are listed in Table 1. 
RNA extraction and Real-time Quantitative Re-
verse Transcription–Polymerase Chain Reaction 
(RT-PCR)  
Total  RNA  was extracted  from  the  cells  in dif-
ferent groups using  TRIzol TM (Invitrogen Life Tech-
nologies).  The purified RNA was quantified by mea-
suring  the  absorbance at 260nm and the  quality  of 
RNA  was  tested by 1% agarose gel electrophoresis. 
1μg of total RNA was reverse transcribed to cDNA in 
a 25 μl   r e a c t i o n   u s i n g   o l i g o d T   ( P r o m e g a )   a n d   M -MLV 
reverse transcriptase (Promega) provided in the  Re-
verse Transcription kit (Promega).  
Q-PCR was performed using a Light Cycler sys-
tem (Roche). Each sample was tested in triplicate and Int. J. Biol. Sci. 2010, 6 
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GAPDH was  used  as an internal control. Primers for 
c-myc, H-ras, p16 and GAPDH are listed in Table 2. 
The  real-time  PCR  data  were  analyzed  using  the 
2-△△CT  relative  quantization  method  following  the 
manufacturer’s  instructions.   T h e   2 5   μ l   r e a c t i o n   m i x-
t u r e   c o n t a i n e d   1   μ l   o f   c o m p l e m e n t a r y   D N A ,   1 2 . 5   μ l   o f  
2×SYBR Green PCR Master Mix, and final concentra-
tion 0.4 μ M   o f   e a c h   p r i m e r .   T h e r m o c y c l e r  conditions 
consisted of an initial activation step at 95 ºC for 10 
minutes, followed by 95 ºC for 30 seconds, 60 ºC for 20 
seconds and 70 ºC 34 seconds for 40 cycles. A dissoci-
ation curve was obtained  for  each  quantitative PCR 
run. 
 
Table 1. The primer sequences for Methylation Specific PCR assay (MSP) 
Genes   Primers  Sequences 
c-myc  methylated forward  5'-TTT TTT TCG TTA ATT TTC GTT TAT C-3' 
  methylated reverse  5'-CTA AAA AAC CCT ACC CTT CTC G-3' 
  unmethylated forward  5'-TTT TTT GTT AAT TTT TGT TTA TTG G-3' 
  unmethylated reverse  5'-CTC TAA AAA ACC CTA CCC TTC TCA-3' 
H-ras  methylated forward  5'-TTT TTG GTT TTT TTC GAG TAA TTT C-3' 
  methylated reverse  5'-CGC GAC CTA CCA TTA ACT ACG-3' 
  unmethylated forward  5'-TTT GGT TTT TTT TGA GTA ATT TTG A-3' 
  unmethylated reverse  5'-CAA ACA CAA CCT ACC ATT AAC TAC AC-3' 
p16(INK4a)  methylated forward  5'-TTA TTA GAG GGT GGG GCG GAT CGC-3' 
  methylated reverse  5'-GAC CCC GAA CCG CGA CCG TAA-3' 
  unmethylated forward  5'-TTA TTA GAG GGT GGG GTG GAT TGT-3' 
  unmethylated reverse   5'-CAA CCC CAA ACC ACA ACC ATA A-3' 
 
Table 2. The primer sequences for Real-time Quantitative PCR 
c-myc  forward  5’-CAA GAG GCG AAC ACA CAA CGT CT-3’ 
reverse  5’-AAC TGT TCT CGT CGT TTC CGC AA-3’ 
H-ras  forward  5’-TGA GGA GCG ATG ACG GAA TA-3’ 
reverse  5’-GTA TCC AGG ATG TCC AAC AG-3’ 
p16(INK4a)  forward  5’-CCCCCACTACCGTAAATGTCCAT-3’ 
  reverse  5’-CTGCCATTTGCTAGCAGTGTGACT-3’ 
GAPDH  forward  5’-GGT GAA GGT CGG AGT CAA CGG A-3’ 
reverse  5’-GAG GGA TCT CGC TCC TGG AAG A-3’ 
 
 
Western blot analysis for protein expression 
C e l l s   w e r e   l y s e d   i n   a   b u f f e r   c o n t a i n i n g   1 5 0   m M  
N a C l ,   5 0   m M   T r i s -HCl, pH 8.0, 0.1% SDS,   1 %   T r i t o n  
X-100, 1 mM orthovanadate, 1 mM phenylmethylsul-
f o n y l   f l u o r i d e ,   1 0   n g / m L   l e u p e p t i n ,   a n d   1 0   n g / m L  
aprotinin. Protein concentrations of the lysates were 
quantified with an absorbance meter (655-nm  wave-
length; Bio-Rad). Each 40-µg sample was separated on 
a  10%  SDS-PAGE  (Bio-Rad  Laboratories,  Inc)  and 
transferred  onto  polyviny  lidene  fluoride  (PVDF) 
membranes that had been pretreated with methanol. 
The membranes were blocked with 5% skim milk or 
1% bovine serum albumin (BSA) in Tris-buffered sa-
line (TBS) buffer (10 mM Tris, 150 mM NaCl, pH 7.9) 
containing 0.05% Tween 20. Blots were probed for 2 
hours at room temperature with primary antibodies 
of C-MYC,  H-RAS,  P16  (Santa Cruz Biotechnology). 
Horseradish peroxidase (HRP)-conjugated secondary 
antibodies  and  an  enhanced  chemiluminescence 
(ECL)  kit  were  used  for  detection.  Reactive  protein 
expression  was  visualized  using  a  CCD  camera 
(Syngene G-Box; Syngene), and quantification of band 
densities was obtained using the Syngene GeneTool 
software. Each  value  was obtained from comparison 
with the level of mouse monoclonal anti-beta-actin. 
Immunofluorescence assay for C-MYC, H-RAS 
and P16 (INK4A) protein expressions 
Cells  were  digested  with  0.25%  trypsin,  and 
subcultured in 24-well plates.  Three wells were ran-
dom l y   s e l e c t e d   f r o m   e a c h   g r o u p   a n d   m a r k e d   as 
C-MYC, H-RAS and P16 (INK4A)  respectively. Cells 
were fixed with 100% alcohol for 30 min. Endogenous 
peroxidase activity was blocked with 3% H2O2 for 30 
min followed with permeabilizing and blocking cells. 
Rat  anti-human  C-MYC  (1:100 dilution, Santa Cruz 
biotechnology, Inc.), rabbit anti-human  H-RAS (1:100 
dilution,  Santa  Cruz  biotechnology,  Inc.)  and rabbit 
anti-human  P16  (1:100  dilution,  Santa  Cruz  biotech-
nology, Inc.) monoclonal antibodies were used. The 
treated  cells  were  incubated  with  antibody 
(300ul/well)  overnight  at  4  ºC,  followed  by  PBS 
washing  3  times.  FITC  tagged  goat  anti-rat  (green Int. J. Biol. Sci. 2010, 6 
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immunofluorescence)  and  TRITC  tagged  goat  an-
ti-rabbit  secondary  antibodies  (red  immunofluores-
cence)  were  added  to  C-MYC,  H-RAS  and 
P16(INK4A)  antibody  incubated  wells  respectively, 
h y b r i d i z a t i o n   w a s   c a r r i e d   o u t  at room temperature for 
2   h .   A f t e r   r e m o v i n g   t h e   s e c o n dary  antibody,  cells 
were w a s h e d   w i t h   P B S   3   t i m e s .   3 visual fields were 
randomly investigated from each well and  the  total 
c e l l   n u m b e r   o f   c e l l s   a n d   t h e   n u m b e r   o f   f l u o r e s-
cence-positive cells in each field were counted under 
phase  contrast  and  fluorescence  microscope  (Nikon 
ECLIPSE  TE2000-U,  Japan),  respectively.  The  fluo-
r e s c e n c e   p o s i t i v e   f r a c t i o n   i n   t o t a l   o b s e r v e d  cells  was 
thus calculated. 
Statistical analysis  
S t a t i s t i c a l   a n a l y s i s   w a s   c a r r i e d   o u t   u s i n g   S P S S  
version 14.0 and one way ANOVA . χ2 test were used 
for a statistical analysis. Differences were considered 
statistically significant when p-value was <0.05. 
Results 
The effects of S-Adenosylmethionine (SAM) on 
the cell growth 
I n   M T T   a s s a y ,   The cell growth inhibition effect of 
SAM  treatment  was  much  higher  in  gastric  cancer 
cells MGC-803 (Fig. 1 A) and colon cancer cells HT-29 
(Fig. 1 B) than in normal cells (Fig. 1 C) ,   a n d   t h i s   d i f-
ference was significant ( p <0.05).  
In colony formation assay, the cell growth inhi-
bition effect of SAM  treatment  was much  higher  in 
gastric cancer cells (Fig. 2 A, B) and colon cancer cells 
(Fig. 2   C ,   D ) than in normal cells (Fig. 2 E, F), and this 
difference was significant (p <0.05). 
 
 
Fig 1. MTT assay showing cell growth viability of cancer cells and normal cells in response to SAM treat-
ment. (A) Gastric cancer cells (MGC-803). (B) Colon cancer cells (HT-29). (C) Normal cells (normal chang liver cells). * 
p <0.05. Int. J. Biol. Sci. 2010, 6 
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F i g   2 .   T h e   c o l o n y   f o r m a t i o n   a s s a y   showing cell growth inhibition of cancer cells and normal cells in re-
s p o n s e   t o   S A M   t r e a t m e n t .   Representative colony images are shown. (A), (B) w i t h   o r   w i t h o u t   S A M   treatment in gastric 
cancer cells (MGC-803). (C), (D) with or without SAM treatment in co l o n   c a n c e r   c e l l s   ( H T -29). (E), (F) with or without 
SAM treatment in normal cells (normal chang liver cells). (G), (H), (I) data analysis of number of colony. * p <0.05. 
 
 
Determining the status of methylation on pro-
moter regions of c-myc and p16 (INK4a) genes by 
Methylation-specific PCR assay (MSP)  
After the treatment with SAM, in MGC-803 cells 
and  HT-29  cells,  the  CpG  islands  on  the  promoter 
region  of  c-myc  were  heavily  methylated  as  evi-
denced  by  all  the  cytosines  remaining  as  cytosines, 
while in the control groups all the cytosines in CpG 
dinucleotides  had  been  converted  to  thymidine, in-
dicating that no cytosine was methylated (Fig.3 A). In 
sharp contrast, the  normal  cells, whose CpG islands 
were  highly  methylated,  no  significant  change  of 
methylation  pattern  was  observed  upon  the  SAM 
treatment. These results demonstrate that SAM could 
specifically  induce  DNA  methylation  on  oncogenic 
c-myc,  which  was  a c t i v e   i n   c a n c e r   c e l l s .   T o   t e s t   t h e  
generality of this observation, we investigated anoth-
er oncogene, H-r a s ,   i n   t h e   s a m e   c e l l s .   S i m i l a r   t o   w h a t  Int. J. Biol. Sci. 2010, 6 
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we observed on c-m y c ,   t h e   H-ras promoter region was 
in  a  non-methylated  state,  which  was  reversed  by 
SAM treatment (Fig.3 B).  
In normal cells, oncogenic c-myc  and  H-ras are 
supposed  to  be  hypermethylated,  therefore  SAM 
treatment should not have any effect on their methy-
lation pattern. To test this hypothesis, normal human 
Chang liver cells were used. Indeed, we found that 
the  c-myc and  H-ras  promoters displayed hyperme-
thylation  before  and  after  SAM  treatment,  with  no 
detectable difference. (Fig.3 A and B) 
I t   h a s   b e e n   f o u n d   t h a t   t u m o r   s u p p r e s s o r   g e n e s 
are  hypermethylated  in  cancer  cells.  To  investigate 
whether SAM treatment can change the methylation 
p a t t e r n   o f   a   t u m o r   s u p p r e s s i o n   g e n e ,   w e   s t u d i e d   t h e  
methylation status of the P16 (INK4 a) promoter. As 
expected, we observed a high level of methylation on 
the  P16 promoter, and that no significant change of 
methylation was found after treating with SAM (Fig.3 
C).  
Quantitative RT-PCR detection of c-myc, H-ras 
and P16 expression level  
It  is  predicted  that  the  methylation  status  of 
promoters is correlated with gene transcription levels. 
We thus investigated the mRNA expression level of 
c-myc, H-ras a n d   P 1 6   i n   t h e   p r e s e n c e   a n d   a b s e n c e   o f  
S A M   t r e a t m e n t .   I n   t h e   c a n c e r   c e l l s   M G C -803  and 
HT-29, c-myc and H-ras expression was much higher 
than  that  in normal cells (p <0.05),  while  P16, as a 
tumor  suppression  gene,  exhibits  the  opposite  pat-
tern. After SAM treatment, c-m y c   a n d   H -ras  expres-
sion  was  dramatically  decreased.  However,  we  ob-
served no difference in P16 expression level before or 
after SAM treatment, so as to the mRNA expression of 
c-m y c ,   H -ras and p16 (INK4a) in normal cells (p >0.05) 
(Fig.4 A, B, C). 
 
 
Fig 3. The analysis of methylation status of c-myc,   H -r a s   a n d   P 1 6 ( I N K 4 a )   p r o m o t e r   b y   M S P  a s s a y   i n   c a n c e r  
cells MGC-803 and HT-2 9   a n d   n o r m a l   c e l l s   w i t h   o r   w i t h o u t   S A M   t r e a t m e n t . (A) c-myc promoter. (B) H-ras 
promter.  (C)  p16  promoter.  M,  DNA  ladder  markers;  ME,  amplified  by  methylated  primers;  UM,  amplified  by 
non-methylated primers. Int. J. Biol. Sci. 2010, 6 
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Fig 4. Quantitative RT-PCR analysis of c-myc, H-ras and p16 expression level in cancer cells and normal 
cells with or without SAM treatment. (A) c-myc mRNA expression. (B) H-ras mRNA expression. (C) p16 mRNA 
expression. The ratio of c-myc, H-ras and p16 mRNA expression and GAPDH mRNA expression was shown. * p <0.05. 
 
Western blot analysis of C-MYC, H-RAS and P16 
(INK4A) proteins 
We investigated the protein expression level of 
C-MYC, H-RAS and P16 in the presence and absence 
of  SAM  treatment to explore the relationship of the 
methylation status of promoters and protein expres-
sion levels. In the cancer cells MGC-803 and  HT-29, 
C-MYC and H-RAS expression was much higher than 
that in normal cells (p <0.05), while P16, as a tumor 
suppression gene, exhibits the opposite pattern. After 
SAM treatment, C-MYC and  H-RAS expression was 
dramatically  decreased.  However,  we  observed  no 
difference in P16 expression level before or after SAM 
treatment, so as to the protein expression of C-MYC, 
H-RAS  and  P16  (INK4a)  in  normal  cells  (p  >0.05) 
(Fig.5 A, B). 
Protein Expressions of C-MYC, H-RAS and P16 
(INK4A) assayed by immunofluorescence  
Given that SAM treatment decreased c-myc and 
H-ras  gene transcription by altering DNA  methyla-
t i o n   o n   i t s   p r o m o t e r   r e g i o n   i n   c a n c e r   c e l l s   b u t   n o t  Int. J. Biol. Sci. 2010, 6 
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normal cells, we then asked whether the protein level 
of  these  genes  were  also  affected  by  SAM.  Protein 
levels  of  c-myc, H-ras  and  P16  was  determined  by 
immunofluorescence,  in  which  antibodies  against 
c-myc,  H-ras  a n d   P 1 6   w e r e   u s e d   t o   v i s u a l i z e   t h e  
presence  and  abundance  of  proteins.  In  untreated 
MGC-803  and  HT-29  cells,  as  much  as  79.39%  and 
79.79% of  cells, respectively, were positive for c-myc 
s t a i n i n g .   A f t e r   S A M   t r e a t m e n t ,   h o w e v e r ,   o n l y   1.85% 
and 3.94%of  cells, respectively, were found having a 
detectable c-myc expression ( F i g .   6   A ) . S i m i l a r   t o   w h a t  
we observed with c-myc,  in untreated MGC-803 and 
HT-29 cells,  as  much  as  79.32% and  78.18% of  cells, 
respectively, were positive for H-RAS staining. After 
SAM treatment, however, only 22.64% and 11.0% of 
cells,  respectively,  were  found  having  a  detectable 
H-RAS expression (Fig. 6 B).  
In contrast, P16 (INK4A) protein levels were low 
with only 20.0% and 15.02% cells positive for staining 
in  MGC-803  control  a n d   S A M   t r e a t e d   c e l l ,   r e s p e c-
tively, indicating that P16 expression was insensitive 
to SAM treatment. (p >0.05) (Fig. 6 C).  
As expected, we found that the protein levels of 
C-MYC and H-RAS in MGC-803 and HT-29 cells were 
significantly  higher  than  that  in  the  normal  cells, 
while  P16  (INK4A)  protein  in  MGC-803  cells  and 
HT-29  cells was much lower than that in the normal 
cells (p <0.05). In the normal cells, those treated with 
SAM showed no difference from the untreated cells in 
terms  of  C-MYC,  H-RAS and P16 protein levels ( p 
>0.05)  (Fig.  6.  A,  B,  C),  demonstrating  that  normal 
cells were not sensitive to SAM treatment.  
 
 
Fig 5. Western blot analysis of C-MYC, H-RAS and P16 expression level i n   c a n c e r   c e l l s   a n d   n o r m a l   c e l l s  
with or without SAM treatment. (A) C-M Y C ,   H -RAS, P16 and Actin protein expression. (B) Data analysis. The ratio 
of C-MYC, H-RAS and P16 protein expression and Actin expression was shown. * p <0.05. Int. J. Biol. Sci. 2010, 6 
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Fig 6. Expression of C-MYC, H-RAS and P16 protein assayed by cell immunofluorescence in cancer cells 
and normal cells with or without SAM treatment. The cells with expressed C-MYC (A), H-RAS (B) and P16 (C) 
were  stained  as  a  green  fluorescence  or  red  fluorescence,  respectively.  The  statistical  analysis  of  expression  of 
C-MYC,H-R A S   a n d   P 1 6   protein assayed by cell immunofluorescence w a s   s h o w n   i n   (D), (E),   a n d   (F) respectively. * p <0.05. 
a) The cells scored by a bright field microscopy (× 200); b) C-MYC o r   H -RAS positive cells scored by counting the number 
of cells with green fluorescence (× 200). 
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Discussion 
The  initiation  and  development  of  cancer  in-
volve the coordinate changes in the expression levels 
of multiple genes. The epigenome is one of the factors 
affecting the regulation of gene expression, so that the 
epigenomic change in genome likely plays a critical 
role in carcinogenesis. The progression of tumors in-
volves the disruption of machinery that keeps gene 
expression at a proper level. For instance, some tumor 
suppressor genes that are normally active in normal 
cells are silenced  and  many  oncogenes  that  are  ne-
cessary  for  migration,  invasion  and  metastasis  are 
activated [16-18].  
The change of methylation patterns in the pro-
moter region of genes i s   o n e   o f   t h e   p a t h w a y s   for re-
gulating gene expression at a transcription level [19, 
20]. Numerous studies have suggested that promoters 
of  tumor  suppressor  genes  are  hypomethylated  or 
even  non-methylated  in  normal  cells.  However, 
hypermethylation  of  tumor  suppressor  genes is fre-
quently  found  in tumor cells, thus  resulting  in  the 
down-regulation of gene expression and an increased 
proliferation  capacity  for  cancerous  cells  [21-24]. 
Meanwhile, accumulated evidence demonstrates that 
inversing the hypermethylated status of tumor  sup-
pressor genes by using demethylated drugs led to the 
restoration of gene expression, thus inhibiting tumor 
cell growth [25-27].  
In  cancer ce l l s ,   a   g lobal hypomethylation on  a 
gene promoter seems to be much less frequent than 
hypermethylation.  However,   t h e   l o s s   o f   D N A   m e-
thylation  often  happens  on the DNA sequence con-
trolling gene transcription [28]. A recent study dem-
onstrated that the gene encoding the protease uroki-
nase (PLAU/uPA) was hypomethylated so that its ex-
pression was up-regulated,   w h i c h   w a s   proposed  to 
correlate with t h e   p r o g r e s s i o n   o f   p r ostate cancer [29]. 
Increased hypomethylation of uPA in cancer invasion 
w a s   i n d u c e d   b y   i n c u b a t i o n   o f   c a n c e r   c e l l s  with 
5-azadeoxycytidine and was associated with upregu-
lation of  uPA  gene [30]. There are other genes exhi-
biting  hypomethylation  and  active  transcription  in 
carcinogenesis,  such  as  S100A4,  PGP9.5,  POMC 
[31-34]. In our study, the oncogenes c-myc and  H-ras 
were hypermethylated and had low expression levels 
in  the  normal  control  c e l l   l i n e .   O n   t h e   c o n t r a r y ,   i n  
tumor  cells, c-myc and  H-ras  had  aberrant hypome-
thylation  and  their  expressions  were  upregulated. 
This hypomethylated status was tumor-specific, pre-
s e n t i n g   a   p o t e n t i a l   m e c h a n i s m   t o   b e   u s e d   a s   a   mole-
cular marker for clinical detection of tumors. 
S-Adenosylmethionine (SAM) is a methyl donor 
for  numerous  methylation  reactions  and  acts  as  an 
inhibitor of intracellular demethylase activity, which 
r e s u l t s   i n   h y p e r m e t h y l a t i o n   o f   D N A  [35]. Zhao et al. 
[36] found that S A M   i n h i b i t e d   t h e   g r o w t h   o f   gastric 
cells  (SGC-7901  and  MKN-45  cells)  and  the  effects 
were  enhanced  with  the  increased  concentration  of 
SAM  and  treatment  time  course.  The  expression  of 
c-myc and uPA in gastric cells significantly decreased 
after SAM treatment and w a s   d u e   t o   partial or com-
plete methylation of c-myc  and  uPA. In vivo, the tu-
mor  volume  was  significantly  lower  in  the  SAM 
treatment group than in the control group. Shukeir N 
et al. [37] tested the hypothesis that cell invasiveness 
and tumorigenesis are driven by hypomethylation of 
genes  in  prostate  cancer  cells.   S A M   t r e a t m e n t s   r e-
sulted i n   a   d o s e - a n d   t i m e -dependent inhibition of key 
genes, such as uPA,  MMP-2, and VEGF  to decrease 
tumor cell invasion in vitro and  in  vivo. No change 
was detected in the levels of expression of genes al-
r e a d y   k n o w n   t o   b e   m e t h y l a t e d ,   s u c h   a s   g l u t a t h i o n e  
S-transferase  P1  and  the  androgen  receptor.  Their 
data  supported  the  hypothesis  that  DNA  hypome-
thylation  controls  the  activation  of  oncogens  and 
provides valuable insight into developing novel the-
rapeutic  strategies  against  this  common  disease, 
which targets the demethylation machinery. 
S A M   i s   a   c y t o t o x i c   d r u g   w h i c h   c a n   k i l l   t u m o r  
cells while n o   t o x i c i t y   h a s   b e e n   o b s e r v e d   i n   n o r m a l  
cells. Lu et al. [38, 39] suggested that predisposition to 
hepatocellular carcinoma (HCC)  could be  partly ex-
plained  by  the  effect  of  SAM  on  cell  growth.  SAM 
inhibited the mitogenic effect of growth factors such 
as  hepatocyte  growth  factor.  Interestingly,  not  only 
could  SAM  control  liver  growth,  it  also  regulated 
apoptosis.  SAM  is  anti-apoptotic  in  normal  hepato-
cytes  but  pro-apoptotic  in liver cancer cells. In liver 
cancer  cells, but  not  in  normal  human  hepatocytes, 
SAM selectively induced Bcl-x(S), an alternative splice 
variant o f   B c l -x(L) that promotes apoptosis. Therefore, 
SAM  could  be  used  as  an  attractive  agent  for  both 
chemopreventio n   a n d   t r e a t m e n t   o f   H C C . The  apop-
totic effect of SAM treatment has also been found in 
c o l o n   c a n c e r   c e l l s ,   b u t   n o   t o x i c   e f f e c t s   i n   n o r m a l   c o l o n  
epithelial cells. This i s   s i m i l a r   t o   t h e   e f f e c t   o f   S A M   o n  
liver  cancer  cells  but  with  different  molecular  me-
chanis m .   S A M   m a y   v i a   d o w n -regulate the expression 
of cFLIP (cFLIP’s over-expression was able to prevent 
SAM-induced apoptosis) to induce apoptosis [40].  
Nowadays,  SAM  has  been  applied  to  clinical 
trials.  SAM  is  used  to  treat  intrahepatic  cholestasis 
and alcoholic liver disease. Human clinical trials have 
showed  that  after  patients  with  cholestasis  given  to Int. J. Biol. Sci. 2010, 6 
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SAM  administration,  cholestasis  and  liver  function 
were improved obviously. Serum levels of TB, AKP, 
A L T ,   A S T ,   G T   w e r e   m a r k e d l y   d e c r e a s e d   i n   t h e   t h i r d  
week, a n d   n o r m a l i z e d   i n   t h e   f o u r t h   w e e k  [41].   S o   w e  
take into account that SAM is a cytoprotective agent 
a g a i n s t   a c u t e   a n d   c h r o n i c   t o x i c   l i v e r   i n j u r y   i n   h u m a n s .  
SAM is also used to treat psychiatric depression. A 
study indicated that 195 patients were given 400 mg 
of intramuscular SAM for 15 days, their depressive 
symptoms showed remission after the treatment with 
SAM  [42].  A l t h o u g h   t h e   s i d e   e f f e c t s   o f   S A M   i n  
short-term use are few, there is no evidence on side 
effect or toxicity in long-term. Besides, a large dose of 
SAM  given  to  patients  may  induce  hypomania  to 
mania in children and adolescents, and the safest dose 
for a depressed patient was not clear [43].  
 In our  present study, we found that SAM  sig-
nificantly inhibited tumor cell growth with a minor 
effect on normal cells in MTT assay (growth rate de-
creased by 22% and 20.3% vs. 6.8% upon treatment in 
gastric cancer, colon cancer and normal cells, respec-
tively), and colony formation assay, suggesting  that 
SAM could be use d   f o r   c a n c e r   t r e a t m e n t .   O u r   d a t a  
also shows that SAM i s   a b l e   t o  effectively induce the 
DNA methylation on oncogenes,   s u c h   a s   c -myc  and 
H-r a s ,   b u t   n o t   t h e   t u m o r   s u p p r e s s o r   g e n e   p 1 6 ,   w h i c h  
p r o b a b l y   i s   d u e   t o   t h e   f a c t   t h a t   i n   c a n c e r   c e l l s ,   t u m o r  
suppressor  genes  are  usually  hypermethylated.  In 
normal  cells,  oncogenic  c-myc  and  H-ras  are  sup-
posed  to  be  hypermethylated,  therefore  SAM  treat-
ment should not have any effect on their methylation 
pattern. To examine this hypothesis, normal human 
Chang liver cell lines were used negative control cells. 
Indeed, we found that the c-myc and H-ras promoters 
displayed  hypermethylation  before  and  after  SAM 
treatment, with no detectable difference. Interestingly, 
i n   n o r m a l   c e l l s   w h e r e   t h e   p 1 6   p r o m o t e r   was hypo-
methylated,  SAM  treatment  was  unable  to  increase 
the methylation level on p16, indicating that normal 
c e l l s   m i g h t   u s e   a   d i f f e r e n t   p a t h w a y   t h a t   i s   S A M   i n-
sensitive for regulating DNA methylation. Taken  to-
gether,  our  data  are  consistent  with  the  hypothesis 
that the hypomethylation of critical genes like c-myc 
and  H-ras plays an important role in carcinogenesis. 
We propose that SAM,  as  a DNA hypermethylating 
agent, could be used as a novel therapeutic drug to 
silence the oncogene c-myc and  H-ras  and  block  the 
progression of gastric and colon cancers.  
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